stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) Shares outstanding
Corcept Therapeutics Incorporated's shares outstanding at the end of fiscal 2025 was $120.0M, up 5.73% from $113.5M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $123.2M. Over the past ten years it has ranged from $106.9M (fiscal 2015) to $126.7M (fiscal 2018); the current reading is higher than 55% of that period. Corcept Therapeutics Incorporated ranks 109th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $120.0M | 5.73% |
| FY2024 | $113.5M | 1.56% |
| FY2023 | $111.7M | (3.64%) |
| FY2022 | $116.0M | (7.94%) |
| FY2021 | $126.0M | 1.42% |
| FY2020 | $124.2M | 1.33% |
| FY2019 | $122.6M | (3.25%) |
| FY2018 | $126.7M | 1.75% |
| FY2017 | $124.5M | 7.21% |
| FY2016 | $116.1M | 8.66% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $123.2M | 4.07% |
| Jun 2026 | $118.4M | 13.36% |
| Mar 2026 | $104.4M | (12.96%) |
| Dec 2025 | $120.0M | 0.46% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $143.4M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| CORT Corcept Therapeutics Incorporated | $123.2M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| ABVX Abivax SA Sponsored ADR compare | $79.6M |
| PTGX Protagonist Therapeutics, Inc. compare | $71.0M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $30.3M |
| PRAX Praxis Precision Medicines, Inc. compare | $29.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CORT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement